261 related articles for article (PubMed ID: 19757304)
21. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
[TBL] [Abstract][Full Text] [Related]
22. Intense reversal of bone marrow angiogenesis after sequential fludarabine-induction and alemtuzumab-consolidation therapy in advanced chronic lymphocytic leukemia.
Molica S; Montillo M; Ribatti D; Mirabelli R; Tedeschi A; Ricci F; Veronese S; Vacca A; Morra E
Haematologica; 2007 Oct; 92(10):1367-74. PubMed ID: 17768114
[TBL] [Abstract][Full Text] [Related]
23. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
24. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
Karlsson C; Hansson L; Celsing F; Lundin J
Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibody therapy of chronic lymphocytic leukemia.
Cheson BD
Cancer Immunol Immunother; 2006 Feb; 55(2):188-96. PubMed ID: 16187090
[TBL] [Abstract][Full Text] [Related]
26. Fludarabine in chronic lymphocytic leukaemia.
Elter T; Hallek M; Engert A
Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
[TBL] [Abstract][Full Text] [Related]
27. [First-line therapy of chronic lymphocytic leukemia in the elderly: be careful with overtreatment].
Bauduer F
Presse Med; 2009 Jan; 38(1):140-2. PubMed ID: 19004611
[No Abstract] [Full Text] [Related]
28. Rituximab therapy of severe aplastic anemia induced by fludarabine and cyclophosphamide in a patient affected by B-cell chronic lymphocytic leukemia.
Castiglioni MG; Scatena P; Pandolfo C; Mechelli S; Bianchi M
Leuk Lymphoma; 2006 Sep; 47(9):1985-6. PubMed ID: 17065021
[No Abstract] [Full Text] [Related]
29. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
30. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia.
Ferrajoli A; Wierda WG; LaPushin R; O'Brien SM; Faderl S; Browning ML; Keating MJ
Eur J Haematol; 2008 Apr; 80(4):296-8. PubMed ID: 18182081
[TBL] [Abstract][Full Text] [Related]
31. [Current concepts in chronic lymphocytic leukemia. Better chances for young patients].
Hallek M; Bergmann M; Goede V; Fingerle-Rowson G; Schweighofer C; Schmitt B; Wendtner CM; Emmerich B
MMW Fortschr Med; 2003 Jul; 145(27-28):46-9. PubMed ID: 14587189
[No Abstract] [Full Text] [Related]
32. Cytotoxic effect of R-etodolac (SDX-101) in combination with purine analogs or monoclonal antibodies on ex vivo B-cell chronic lymphocytic leukemia cells.
Robak P; Linke A; Cebula B; Robak T; Smolewski P
Leuk Lymphoma; 2006 Dec; 47(12):2625-34. PubMed ID: 17169808
[TBL] [Abstract][Full Text] [Related]
33. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
34. Current and developing chemotherapy for CLL.
Montserrat E
Med Oncol; 2002; 19 Suppl():S11-9. PubMed ID: 12180487
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibody licensed for third-line treatment of B-cell chronic lymphocytic leukemia.
Thompson CA
Am J Health Syst Pharm; 2001 Jul; 58(13):1174. PubMed ID: 11449871
[No Abstract] [Full Text] [Related]
36. Update on monoclonal antibody therapy in chronic lymphocytic leukemia.
Zent CS; Kay NE
Clin Adv Hematol Oncol; 2004 Feb; 2(2):107-13. PubMed ID: 16163170
[TBL] [Abstract][Full Text] [Related]
37. Purine nucleoside analogues and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era.
Nabhan C; Gartenhaus RB; Tallman MS
Leuk Res; 2004 May; 28(5):429-42. PubMed ID: 15068894
[TBL] [Abstract][Full Text] [Related]
38. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab.
Williamson TS
Clin J Oncol Nurs; 2001; 5(6):287-8. PubMed ID: 11899633
[No Abstract] [Full Text] [Related]
40. Alemtuzumab for treatment of lymphoproliferative disorders.
Haematologica; 2004 Dec; 89(12):1419. PubMed ID: 15590389
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
